High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine | Zendy

Jorge Romaguera | Zendy; Luis Fayad | Zendy; Maria Alma Rodriguez | Zendy; Kristine Broglio | Zendy; Frederick Hagemeister | Zendy; Barbara Pro | Zendy; Peter McLaughlin | Zendy; Anas Younes | Zendy; Felipe Samaniego | Zendy; André Goy | Zendy; Andreas H. Sarris | Zendy; Nam H. Dang | Zendy; Michael Wang | Zendy; Virginia Beasley | Zendy; L. Jeffrey Medeiros | Zendy; Ruth L. Katz | Zendy; Harish K. Gagneja | Zendy; Barry I. Samuels | Zendy; Terry L. Smith | Zendy; Fernando Cabanillas | Zendy

Open Access

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Author(s) -

Jorge Romaguera,

Luis Fayad,

Maria Alma Rodriguez,

Kristine Broglio,

Frederick Hagemeister,

Barbara Pro,

Peter McLaughlin,

Anas Younes,

Felipe Samaniego,

André Goy,

Andreas H. Sarris,

Nam H. Dang,

Michael Wang,

Virginia Beasley,

L. Jeffrey Medeiros,

Ruth L. Katz,

Harish K. Gagneja,

Barry I. Samuels,

Terry L. Smith,

Fernando Cabanillas

Publication year - 2005

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.01.1825

Subject(s) - medicine , rituximab , cytarabine , regimen , gastroenterology , vincristine , mantle cell lymphoma , cyclophosphamide , surgery , toxicity , chemotherapy , lymphoma

To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research